Host-mycobacteria conflict: Immune responses of the host vs. the mycobacteria TLR2 and TLR4 ligands and concomitant host-directed therapy

被引:14
|
作者
Pattanaik K.P. [1 ]
Sengupta S. [1 ]
Jit B.P. [2 ]
Kotak R. [1 ]
Sonawane A. [3 ]
机构
[1] KIIT School Of Biotechnology, KIIT University, Odisha, Bhubaneswar
[2] Department of Biochemistry, All India Institute of Medical Sciences, New Delhi
[3] Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Madhya Pradesh
关键词
Host directed therapy; Host pathogen interaction; Mycobacterium tuberculosis; Pathogen associated molecular pattern; Pathogen recognition receptors; Toll like receptors;
D O I
10.1016/j.micres.2022.127153
中图分类号
学科分类号
摘要
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is one of the most grievous infectious diseases with long-term morbidity and unpredicted mortality rates globally. Thus, understanding the host-pathogen interactions to develop potential drugs is the most focused area of research. Mtb has many antigens communicating with host cells via various pattern recognition receptors (PRRs). From which, toll-like receptors-2 and 4 (TLR2 and 4) are two major PRRs that provide the primary immune response to Mtb infection of the respiratory tract. As a result, the TLR-mycobacterium antigen interaction triggers a variety of crucial innate immune signalling mechanisms such as phagosome maturation, oxidative stress, elicitation of cell deaths, production of proinflammatory cytokines, and eventually associates with the adaptive immune response to establish infection. Despite the extensive investigations on TLR2 and 4 Mtb ligands that have a significant role in the immune defence system, there are still many unsolved concerns driving researchers to explore the obscures. This review focuses on the host immune modulation due to Mtb-TLR2 and 4 ligand interaction. Subsequently, the host TLR2 and 4 immune signals in cooperation with other PRRs and successive cytokine expressions are discussed. Also highlighted are some recent findings on host-directed therapy related to TLRs that aid in developing novel immunotherapeutic prospects for the better control of Mtb infection. © 2022 Elsevier GmbH
引用
收藏
相关论文
共 50 条
  • [31] Mycobacterium tuberculosis PE_PGRS38 Enhances Intracellular Survival of Mycobacteria by Inhibiting TLR4/NF-κB-Dependent Inflammation and Apoptosis of the Host
    Ullah, Hayan
    Shi, Xiaoxia
    Taj, Ayaz
    Cheng, Lin
    Yan, Qiulong
    Sha, Shanshan
    Ahmad
    Kang, Jian
    Haris, Muhammad
    Ma, Xiaochi
    Ma, Yufang
    BIOLOGY-BASEL, 2024, 13 (05):
  • [32] Distinct immune responses in TLR2, TLR4 or MyD88 deficient mice following pseuepomonas aeruginosa lung infection
    Lin, TJ
    Power, M
    Maydanski, E
    Marshall, JS
    CHEST, 2004, 126 (04) : 849S - 850S
  • [33] Fibronectin (FN) cooperated with TLR2/TLR4 receptor to promote innate immune responses of macrophages via binding to integrin β1
    Fei, Dongsheng
    Meng, Xianglin
    Yu, Wei
    Yang, Songlin
    Song, Ning
    Cao, Yanhui
    Jin, Songgen
    Dong, Lina
    Pan, Shangha
    Zhao, Mingyan
    VIRULENCE, 2018, 9 (01) : 1588 - 1600
  • [34] The role of RAGE in host pathology and crosstalk between RAGE and TLR4 in innate immune signal transduction pathways
    Prantner, Daniel
    Nallar, Shreeram
    Vogel, Stefanie N.
    FASEB JOURNAL, 2020, 34 (12): : 15659 - 15674
  • [35] Pseudomonas aeruginosa-dependent upregulation of TLR2 influences host responses to a secondary Staphylococcus aureus infection
    Shin, Hee-Sung
    Lee, Jung-Hoon
    Paek, Se-Hwan
    Jung, Yong Woo
    Ha, Un-Hwan
    PATHOGENS AND DISEASE, 2013, 69 (02): : 149 - 156
  • [36] Extracellular vesicles modulate host-microbe responses by ligand-dependent inhibition of TLR2 activity
    van Bergenhenegouwen, J.
    Rutten, L.
    Kettelarij, N.
    Kraneveld, A. D.
    Garssen, J.
    Vos, A. P.
    ALLERGY, 2014, 69 : 531 - 532
  • [37] Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment
    Shangzi Wang
    Igor A. Astsaturov
    Catherine A. Bingham
    Kenneth M. McCarthy
    Margaret von Mehren
    Wei Xu
    R. Katherine Alpaugh
    Yong Tang
    Bruce A. Littlefield
    Lynn D. Hawkins
    Sally T. Ishizaka
    Louis M. Weiner
    Cancer Immunology, Immunotherapy, 2012, 61 : 49 - 61
  • [38] Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment
    Wang, Shangzi
    Astsaturov, Igor A.
    Bingham, Catherine A.
    McCarthy, Kenneth M.
    von Mehren, Margaret
    Xu, Wei
    Alpaugh, R. Katherine
    Tang, Yong
    Littlefield, Bruce A.
    Hawkins, Lynn D.
    Ishizaka, Sally T.
    Weiner, Louis M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (01) : 49 - 61
  • [39] Pathogen induction of CXCR4/TLR2 cross-talk impairs host defense function
    Hajishengallis, George
    Wang, Min
    Liang, Shuang
    Triantafilou, Martha
    Triantafilou, Kathy
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (36) : 13532 - 13537
  • [40] CsHscB as a novel TLR2 agonist from a carcinogenic liver fluke Clonorchis sinensis modulates host immune response
    Yan, C.
    Fang, F.
    Zhang, Y. -Z.
    Wu, J.
    Dong, X.
    Zhang, Y.
    Liu, H. -L.
    Yu, Q.
    Wang, L.
    Li, X. -Y.
    Wang, Y.
    Tang, R. -X.
    Zheng, K. -Y.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1197 - 1197